Modern nuclear imaging for paragangliomas: Beyond SPECT

Journal of Nuclear Medicine

Volumn 53, Issue 2, 2012, Pages 264-274

  Taïeb, David ^a   Neumann, Hartmut ^b   Rubello, Domenico ^c   Al Nahhas, Adil ^d   Guillet, Benjamin ^a   Hindié, Elif ^e  

^a TIMONE HOSPITAL   (France)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Civile Hospital Santa Mariadella Misericordia   (Italy)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Genetics; Paraganglioma; PET CT; Positron emission tomography; Radiopharmaceuticals

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 6 FLUORODOPAMINE F 18; FLUORODEOXYGLUCOSE F 18; GADOTERIC ACID; GALLIUM 68; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HYDROXYEPHEDRINE C 11; PENTETATE INDIUM IN 111; SOMATOSTATIN; SOMATOSTATIN RECEPTOR 2; SUCCINATE DEHYDROGENASE; TRACER; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

CATECHOLAMINE NERVE CELL; CONTRAST SENSITIVITY; DECARBOXYLATION; DIAGNOSTIC IMAGING; DOPAMINERGIC TRANSMISSION; DRUG TUMOR LEVEL; GENE MUTATION; GENETIC SUSCEPTIBILITY; GLUCOSE METABOLISM; HETEROZYGOTE; HUMAN; IMAGE QUALITY; ISOTOPE TRACING; LIVER METASTASIS; METASTASIS POTENTIAL; MOLECULAR GENETICS; MOLECULAR IMAGING; PARAGANGLIOMA; PATHOLOGICAL ANATOMY; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SIPPLE SYNDROME; SYNDROME DELINEATION; THREE DIMENSIONAL IMAGING; TUMOR CLASSIFICATION; TUMOR GENE; TUMOR LOCALIZATION;

DIAGNOSTIC IMAGING; GENOTYPE; HUMANS; MUTATION; NUCLEAR MEDICINE; PARAGANGLIOMA; PHENOTYPE;

EID: 84856799879     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.098152     Document Type: Review

References (93)

1. Karasek D, Frysak Z, Pacak K. Genetic testing for pheochromocytoma. Curr Hypertens Rep. 2010;12:456-464.
2. Mannelli M, Castellano M, Schiavi F, et al. Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab. 2009;94:1541-1547.
3. Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005;23:8812-8818. (Pubitemid 46211527)
4. Cascón A, Pita G, Burnichon N, et al. Genetics of pheochromocytoma and paraganglioma in Spanish patients. J Clin Endocrinol Metab. 2009;94:1701-1705.
5. Erlic Z, Rybicki L, Peczkowska M, et al. Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin Cancer Res. 2009;15: 6378-6385.
6. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287:848-851. (Pubitemid 30084326)
7. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet. 2001;69:49-54. (Pubitemid 32614017)
8. Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet. 2000;26:268-270.
9. Boedeker CC, Erlic Z, Richard S, et al. Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2009;94:1938-1944.
10. Neumann HP, Erlic Z, Boedeker CC, et al. Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res. 2009;69:3650-3656.
11. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 2003;63:5615-5621. (Pubitemid 37139886)
12. Hao HX, Khalimonchuk O, Schraders M, et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science. 2009;325:1139-1142.
13. Bayley JP, Kunst HP, Cascon A, et al. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol. 2010;11:366-372.
14. Burnichon N, Briere JJ, Libe R, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010;19:3011-3020.
15. Korpershoek E, Favier J, Gaal J, et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab. 2011;96:E1472-E1476.
16. Qin Y, Yao L, King EE, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet. 2010;42:229-233.
17. Yao L, Schiavi F, Cascon A, et al. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA. 2010;304: 2611-2619.
18. Neumann HP, Sullivan M, Winter A, et al. Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites. J Clin Endocrinol Metab. 2011;96:E1279-E1282.
19. Comino-Méndez I, Gracia-Aznarez FJ, Schiavi F, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet. 2011;43:663-667.
20. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366:665-675. (Pubitemid 41176020)
21. Ayala-Ramirez M, Feng L, Johnson MM, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011;96:717-725.
22. Havekes B, King K, Lai EW, Romijn JA, Corssmit EP, Pacak K. New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf). 2010;72:137-145.
23. Taïeb D, Rubello D, Al-Nahhas A, Calzada M, Marzola MC, Hindie E. Modern PET imaging for paragangliomas: relation to genetic mutations. Eur J Surg Oncol. 2011;37:662-668.
24. 111In-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med. 2008;49:1613-1619.
25. Kaltsas GA, Mukherjee JJ, Grossman AB. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours. Ann Oncol. 2001;12(suppl 2):S47-S50. (Pubitemid 33069687)
26. 111In-octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86:685-693.
27. Tenenbaum F, Lumbroso J, Schlumberger M, et al. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med. 1995;36:1-6.
28. Bustillo A, Telischi F, Weed D, et al. Octreotide scintigraphy in the head and neck. Laryngoscope. 2004;114:434-440. (Pubitemid 38391905)
29. Duet M, Sauvaget E, Petelle B, et al. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med. 2003;44:1767-1774. (Pubitemid 39663308)
30. 123I- metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med. 2008;49:1232-1237.
31. 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma. Nucl Med Commun. 1998;19:735-742.
32. Schmidt M, Fischer E, Dietlein M, et al. Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas. Eur J Nucl Med Mol Imaging. 2002;29:1571-1580.
33. Telischi FF, Bustillo A, Whiteman ML, et al. Octreotide scintigraphy for the detection of paragangliomas. Otolaryngol Head Neck Surg. 2000;122: 358-362. (Pubitemid 30155313)
34. 18F FDOPA-PET in the localization of extra-adrenal paragangliomas: the case for a patient-tailored use of nuclear imaging modalities. Clin Endocrinol (Oxf). 2011;74:21-29.
35. Shulkin BL, Koeppe RA, Francis IR, Deeb GM, Lloyd RV, Thompson NW. Pheochromocytomas that do not accumulate metaiodobenzylguanidine: localization with PET and administration of FDG. Radiology. 1993;186:711-715. (Pubitemid 23073512)
36. 18fluorine-fluoro-2-deoxy-D-glucose PET. Radiology. 1999;212:35-41.
37. 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med. 2009;50:858-864.
38. 18F fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91:498-505.
39. Shulkin BL,Wieland DM, Schwaiger M, et al. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med. 1992;33: 1125-1131.
40. 18F-fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension. 2001;38:6-8.
41. Saveanu A, Muresan M, De Micco C, et al. Expression of somatostatin receptors, dopamine D2 receptors, noradrenaline transporters and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2011;18:287-300.
42. 18F DOPA whole body PET - initial results. Radiology. 2002;222: 507-512.
43. 18F-fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med. 2007;48:1599-1606.
44. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32:724.
45. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338-1347. (Pubitemid 37247950)
46. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-282. (Pubitemid 30167697)
47. 11C hydroxyephedrine PET. Radiology. 2004;230: 423-428.
48. 123I-MIBG SPECT/CT. J Nucl Med. 2006;47:1635-1642.
49. Timmers HJ, Carrasquillo JA, Whatley M, et al. Usefulness of standardized uptake values for distinguishing adrenal glands with pheochromocytoma from normal adrenal glands by use of 6-18F-fluorodopamine PET. J Nucl Med. 2007;48:1940-1944. (Pubitemid 350232301)
50. 18F-DOPA PET/CT) for detecting pheochromocytoma. Eur J Nucl Med Mol Imaging. 2010;37:484-493.
51. 18F-FDG PET/CT. J Nucl Med. 2004;45:1340-1343.
52. Leboulleux S, Deandreis D, Escourrou C, et al. Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy. Eur J Endocrinol. 2011;164:89-94.
53. 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94:4757-4767.
54. 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab. 2010;95:2800-2810.
55. Mackenzie IS, Gurnell M, Balan KK, Simpson H, Chatterjee K, Brown MJ. The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidinenegative phaeochromocytoma. Eur J Endocrinol. 2007;157:533-537. (Pubitemid 350018459)
56. 123I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab. 2009;94:3922-3930.
57. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med. 2009;50:513-519.
58. 18F-fluorodihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer. 2009; 16:255-265.
59. 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma. Nucl Med Commun. 2011;32:575-582.
60. 18F-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). Clin Endocrinol (Oxf). 2009;71:11-17.
61. 18F-fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol. 2006;13:187-197.
62. 123I-MIBG SPECT: a study of patients being evaluated for pheochromocytoma. J Nucl Med. 2007;48:1077-1083.
63. 18F-fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol. 2007;156: 483-487.
64. 18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature? J Nucl Med. 2009; 50:711-717.
65. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol. 2011;13:769-775.
66. 68Ga-DOTATATE PET in malignant abdominal paraganglioma. Eur J Nucl Med Mol Imaging. 2006;33:506.
67. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun. 2007;28:359-363.
68. 68Ga-DOTA-NOC PET. Biomed Pharmacother. 2008;62: 667-671.
69. 18F-DOPA PET/CT positive pheochromocytoma: a case report. Clin Nucl Med. 2011;36:124-126.
70. 68Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study. Eur Radiol. October 5, 2011 [Epub ahead of print].
71. Rahbar K, Kies P, Stegger L, Juergens KU, Weckesser M. Discrepancy between glucose metabolism and sympathetic nerve terminals in a patient with metastatic paraganglioma. Eur J Nucl Med Mol Imaging. 2008;35:687.
72. 131I-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab. 2003; 88:4083-4087.
73. 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrinol (Oxf). 2008;69:580-586.
74. 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011;38:865-873.
75. Zelinka T, Timmers HJ, Kozupa A, et al. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocr Relat Cancer. 2008;15:311-323. (Pubitemid 351449749)
76. Timmers HJ, Kozupa A, Chen CC, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25:2262-2269. (Pubitemid 46954653)
77. 68Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2010;37:722-727.
78. Poeppel TD, Yuece A, Boy C, et al. Novel SDHD gene mutation (H102R) in a patient with metastatic cervical paraganglioma effectively treated by peptide receptor radionuclide therapy. J Clin Oncol. 2011;29:e812-e815.
79. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging. 2003;30:689-694.
80. 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab. 2011;96:2779-2785.
81. King KS, Whatley MA, Alexopoulos DK, et al. The use of functional imaging in a patient with head and neck paragangliomas. J Clin Endocrinol Metab. 2010; 95:481-482.
82. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 2008;13:472-482. (Pubitemid 351766797)
83. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009;23:537-548.
84. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029-1033.
85. Pollard PJ, Briere JJ, Alam NA, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet. 2005;14:2231-2239. (Pubitemid 41418022)
86. Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005;7:77-85. (Pubitemid 40126384)
87. MacKenzie ED, Selak MA, Tennant DA, et al. Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol Cell Biol. 2007;27:3282-3289. (Pubitemid 46685207)
88. Bardella C, Pollard PJ, Tomlinson I. SDH mutations in cancer. Biochim Biophys Acta. 2011;1807:1432-1443.
89. Pollard PJ, El-Bahrawy M, Poulsom R, et al. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J Clin Endocrinol Metab. 2006;91:4593-4598. (Pubitemid 44833443)
90. Favier J, Briere JJ, Burnichon N, et al. The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS ONE. 2009;4:e7094.
91. López-Jiménez E, Gomez-Lopez G, Leandro-Garcia LJ, et al. Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol. 2010;24:2382-2391.
92. Burnichon N, Vescovo L, Amar L, et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet. 2011;20:3974-3985.
93. Span PN, Rao JU, Oude Ophuis B, et al. Overexpression of the natural antisense hypoxia-inducible factor-1alpha transcript is associated with malignant phaeochromocytoma/paraganglioma. Endocr Relat Cancer. 2011;18:323-331.